Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
12:16am, Saturday, 31'st May 2025
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has
Moderna, Inc. (MRNA) Bernstein 41st Annual Strategic Decisions Conference Call Transcript
03:15pm, Thursday, 29'th May 2025
Moderna, Inc. (NASDAQ:MRNA ) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Court
HHS cancels Moderna contract for development of bird flu vaccine for humans
12:15pm, Thursday, 29'th May 2025
The Department of Health and Human Services announced this week that it had canceled its contract with Moderna to develop a bird flu mRNA vaccine for humans. In a statement, the department wrote that
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
12:10pm, Thursday, 29'th May 2025
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
HHS cancels Moderna bird flu deal
08:47am, Thursday, 29'th May 2025
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
US cancels more $700 million funding for Moderna bird flu vaccine
06:06pm, Wednesday, 28'th May 2025
The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the drugmak
Moderna Announces Update on Investigational Pandemic Influenza Program
06:00pm, Wednesday, 28'th May 2025
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMB
Cautious? Risky? Our Volatility Scorecard Can Help
10:13am, Tuesday, 27'th May 2025
Subscribers to Chart of the Week received this commentary on Sunday, May 11.
Moderna to Present at Upcoming Conferences in June 2025
07:00am, Tuesday, 27'th May 2025
CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Jefferies Global Health Care Conference,
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine
10:46am, Monday, 26'th May 2025
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
Will Moderna's Rally Continue?
06:35am, Monday, 26'th May 2025
Moderna (NASDAQ: MRNA) has caught the market off guard with a significant recovery in recent days – reaching current levels of approximately $27 after hitting a five-year low of $23.15 last week –
Moderna files application for updated COVID vaccine
04:19pm, Friday, 23'rd May 2025
Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug Administration.
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
04:05pm, Friday, 23'rd May 2025
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spike
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
11:51am, Thursday, 22'nd May 2025
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
Moderna Stock Looks Ripe for a Short Squeeze
07:15am, Thursday, 22'nd May 2025
Moderna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 mon
